TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group.
C FabbroniG GrignaniB VincenziE FumagalliT M De PasA MazzoccaM A PantaleoA BrunelloG G BaldiA BoglioneS FatigoniA BerrutiM GiordanoA MarrariA P Dei TosA S AlbertonS AlibertiL CarlucciE RulliP G CasaliR SanfilippoPublished in: ESMO open (2024)
While the primary endpoint of the study was not met, we noticed a subgroup of patients with a markedly discrepant TTP with trabectedin in comparison to previous therapy (GMI <0.5 or >2, the latter including some patients with a long TTP with trabectedin). A mismatch between PFS and overall survival was observed, possibly due to the natural history of the two different histologies and the availability of further lines in LMS.